This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field. Articles from the bibliography that are reprinted in this issue are indicated with an asterisk (*).
References
- Avasthi A, Sahoo S, Grover S: Clinical practice guidelines for cognitive behavioral therapy for psychotic disorders. Indian J Psychiatry 2020; 62:S251–S262 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Azargoonjahromi A: Current findings and potential mechanisms of KarXT (xanomeline-trospium) in schizophrenia treatment. Clin Drug Investig 2024; 44:471–493 [DOI] [PubMed] [Google Scholar]
- Barnett I, Torous J, Staples P, et al. : Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology 2018; 43:1660–1666 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ben-Zeev D, Brian R, Wang R, et al. : CrossCheck: integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. Psychiatr Rehabil J 2017; 40:266–275 [DOI] [PMC free article] [PubMed] [Google Scholar]
- *Bighelli I, Salanti G, Huhn M, et al. : Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry 2018; 17:316–329 [DOI] [PMC free article] [PubMed] [Google Scholar]
- *Camacho E, Torous J: Impact of digital literacy training on outcomes for people with serious mental illness in community and inpatient settings. Psychiatr Serv 2023; 74:534–538 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chengappa KNR, Gannon JM, Joshi YB: A call to psychiatrists: deprescription of unnecessary anticholinergic medications in schizophrenia must start now. Am J Psychiatry 2025; 182:319–321 [DOI] [PubMed] [Google Scholar]
- Chepke C, Benning B, Cicero S, et al. : Investigating real-world benztropine usage patterns in movement disorders: claims analysis and health care provider survey results. Prim Care Companion CNS Disord 2023; 25:22m03472 PubMed [DOI] [PubMed] [Google Scholar]
- Claxton A, Konis G, Kaul I, et al. : Long-term metabolic outcomes associated with KarXT (xanomeline and trospium): interim results from pooled, long-term safety studies EMERGENT-4 and EMERGENT-5; in Annual Congress of the Schizophrenia International Research Society, Florence, Italy, April 3–7, 2024 [Google Scholar]
- Firth J, Cotter J, Torous J, et al. : Mobile phone ownership and endorsement of “mHealth” among people with psychosis: a meta-analysis of cross-sectional studies. Schizophr Bull 2016; 42:448–455 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gannon JM, Lupu A, Brar J, et al. : Deprescribing anticholinergic medication in the community mental health setting: a quality improvement initiative. Res Social Adm Pharm 2021; 17:1841–1846 [DOI] [PubMed] [Google Scholar]
- Hardy KV: Fact Sheet: Cognitive-Behavioral Therapy for Psychosis (CBTp). Rockville, MD, Substance Abuse and Mental Health Services Administration, 2017. https://sites.utexas.edu/mental-health-institute/files/2024/07/CBT-P-Fact-Sheet_Kate-Hardy.pdf [Google Scholar]
- Harper DJ, Townsend S: From the margins to the NICE guidelines: British clinical psychology and the development of cognitive behaviour therapy for psychosis, 1982–2002. Hist Human Sci 2022; 35:260–290 [Google Scholar]
- Joshi YB, Molina JL, Braff DL, et al. : Sensitivity of schizophrenia endophenotype biomarkers to anticholinergic medication burden. Am J Psychiatry 2023; 180:519–523 [DOI] [PubMed] [Google Scholar]
- Joshi YB, Thomas ML, Braff DL, et al. : Anticholinergic medication burden–associated cognitive impairment in schizophrenia. Am J Psychiatry 2021; 178:838–847 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaul I, Cohen EA, Miller AC, et al. : Maintenance of efficacy of KarXT (xanomeline and trospium) in schizophrenia; in Annual Congress of the Schizophrenia International Research Society, Florence, Italy, April 3–7, 2024 [Google Scholar]
- Kaul I, Sawchak S, Correll CU, et al. : Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomized, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2024; 403:160–170 [DOI] [PubMed] [Google Scholar]
- Kaul I, Sawchak S, Walling DP, et al. : Efficacy and safety of xanomeline/trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 2024; 81:749–756 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kopelovich SL, Basco-Ramirez M, Stacy M, et al. : Position Statement of the Administration of Cognitive Behavioral Therapy for Psychosis in Routine Care Settings. Alexandria, VA, National Association of State Mental Health Program Directors, 2021 [Google Scholar]
- Lupu AM, Clinebell K, Gannon JM, et al. : Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry 2017; 78:e1270–e1275 [DOI] [PubMed] [Google Scholar]
- Lupu AM, MacCamy KL, Gannon JM, et al. : Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry 2021; 33:80–92 [DOI] [PubMed] [Google Scholar]
- Mancini V, Latreche C, Fanshawe JB, et al. : Anticholinergic burden and cognitive function in psychosis: a systematic review and meta-analysis. Am J Psychiatry 2025; 182:349–359 [DOI] [PubMed] [Google Scholar]
- Paul SM, Yohn SE, Popiolek M, et al. : Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry 2022; 179:611–627 [DOI] [PubMed] [Google Scholar]
- Routine Administration of Cognitive Behavioral Therapy for Psychosis as the Standard of Care for Individuals Seeking Treatment for Psychosis: State of the Science and Implementation Considerations for Key Stakeholders. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2021 [Google Scholar]
- Spaniel F, Vohlídka P, Hrdlicka J, et al. : ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res 2008; 98:312–317 [DOI] [PubMed] [Google Scholar]
- Turner DT, Burger S, Smit F, et al. : What constitutes sufficient evidence for case formulation–driven CBT for psychosis? Cumulative meta-analysis of the effect on hallucinations and delusions. Schizophr Bull 2020; 46:1072–1085 [DOI] [PMC free article] [PubMed] [Google Scholar]
- *Turner DT, Reijnders M, van der Gaag M, et al. : Efficacy and moderators of cognitive behavioural therapy for psychosis versus other psychological interventions: an individual-participant data meta-analysis. Front Psychiatry 2020; 11:402. [DOI] [PMC free article] [PubMed] [Google Scholar]
